1 min read
Add as a preferred source on GoogleCytoMed Therapeutics Gets Nasdaq Notice Over $1 Bid Deficiency
The company has until April 5, 2027, to restore compliance after its closing bid price remained below $1 for 30 consecutive business days.
CytoMed Therapeutics Limited (GDTC) received a Nasdaq noncompliance notice after its closing bid price remained below $1 for 30 consecutive business days.
The company has until April 5, 2027, to restore compliance with Nasdaq’s minimum bid-price requirement. It must maintain a closing bid price of at least $1 to meet the standard.
The notice concerns the company’s continued listing compliance and sets the April 5 deadline for corrective action.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.